IL1B and colitis: Preclinical studies supported the effectiveness of anti-IL-1β monoclonal antibodies 7F IgG and FL-BsAb1/17 in mitigating colitis (44, 45), while anakinra showed efficacy in the UC model of primary anti-TNF non-responders (46).